Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Itch and Sleep Improvements with Baricitinib in Patients with Atopic Dermatitis: A Post Hoc Analysis of 3 Phase 3 Studies
Timo Buhl, David Rosmarin, E. Serra‐Baldrich, et al.
Dermatology and Therapy (2021) Vol. 11, Iss. 3, pp. 971-982
Open Access | Times Cited: 21

Showing 21 citing articles:

Oral Janus kinase inhibitors for atopic dermatitis
Daniela Mikhaylov, Benjamin Ungar, Yael Renert‐Yuval, et al.
Annals of Allergy Asthma & Immunology (2023) Vol. 130, Iss. 5, pp. 577-592
Open Access | Times Cited: 35
Baricitinib Safety for Events of Special Interest in Populations at Risk: Analysis from Randomised Trial Data Across Rheumatologic and Dermatologic Indications
Peter C. Taylor, Thomas Bieber, Rieke Alten, et al.
Advances in Therapy (2023) Vol. 40, Iss. 4, pp. 1867-1883
Open Access | Times Cited: 25
Pharmacological Effects of Polyphenol Phytochemicals on the JAK-STAT Signaling Pathway
Qianqian Yin, Longyun Wang, Haiyang Yu, et al.
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 54
Baricitinib: The First Jak Inhibitor Approved in Europe for the Treatment of Moderate to Severe Atopic Dermatitis in Adult Patients
Giulia Radi, Oriana Simonetti, Giulio Rizzetto, et al.
Healthcare (2021) Vol. 9, Iss. 11, pp. 1575-1575
Open Access | Times Cited: 33
Baricitinib: A Review in Moderate to Severe Atopic Dermatitis
Sheridan M. Hoy
American Journal of Clinical Dermatology (2022) Vol. 23, Iss. 3, pp. 409-420
Open Access | Times Cited: 24
A review on the chemistry and pharmacological properties of benzodiazepine motifs in drug design
Olayinka O. Tolu-Bolaji, Samuel O. Sojinu, Adebola P. Okedere, et al.
Arab Journal of Basic and Applied Sciences (2022) Vol. 29, Iss. 1, pp. 287-306
Open Access | Times Cited: 23
Insights into atopic dermatitis pathogenesis lead to newly approved systemic therapies
Anna M. Trier, Brian Kim
British Journal of Dermatology (2022) Vol. 188, Iss. 6, pp. 698-708
Open Access | Times Cited: 20
Nemolizumab Improves Patient-Reported Symptoms of Atopic Dermatitis with Pruritus: Post Hoc Analysis of a Japanese Phase III Randomized Controlled Trial
Kenji Kabashima, Takayo Matsumura, Hiroshi Komazaki, et al.
Dermatology and Therapy (2023) Vol. 13, Iss. 4, pp. 997-1011
Open Access | Times Cited: 8
Baricitinib Rapidly Improves Skin Pain Resulting in Improved Quality of Life for Patients with Atopic Dermatitis: Analyses from BREEZE-AD1, 2, and 7
Jacob P. Thyssen, Timo Buhl, Pablo Fernández‐Peñas, et al.
Dermatology and Therapy (2021) Vol. 11, Iss. 5, pp. 1599-1611
Open Access | Times Cited: 18
Early Itch Response with Abrocitinib Is Associated with Later Efficacy Outcomes in Patients with Moderate-to-Severe Atopic Dermatitis: Subgroup Analysis of the Randomized Phase III JADE COMPARE Trial
Sonja Ständer, Shawn G. Kwatra, Jonathan I. Silverberg, et al.
American Journal of Clinical Dermatology (2022) Vol. 24, Iss. 1, pp. 97-107
Open Access | Times Cited: 12
Indirect Treatment Comparison of Baricitinib versus Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis
Marjolein de Bruin‐Weller, E. Serra‐Baldrich, S. Barbarot, et al.
Dermatology and Therapy (2022) Vol. 12, Iss. 6, pp. 1481-1491
Open Access | Times Cited: 11
Response of Darier Disease Following Treatment With Baricitinib
José Manuel Busto Leis, Guillermo Servera-Negre, Ander Paulo Mayor Ibarguren, et al.
JAMA Dermatology (2022) Vol. 158, Iss. 6, pp. 699-699
Closed Access | Times Cited: 9
Baricitinib treatment rapidly improves the four signs of atopic dermatitis assessed by Eczema Area and Severity Index (EASI) clinical subscores
Andreas Wollenberg, Dagmar Simon, Kanokvalai Kulthanan, et al.
Journal of the European Academy of Dermatology and Venereology (2023) Vol. 38, Iss. 4, pp. 695-702
Open Access | Times Cited: 4
Baricitinib rapidly and sustainably relieves a patient from chronic pruritus of unknown origin refractory to dupilumab
Thomas Buttgereit, Eva Grekowitz, Martin Metz
JAAD Case Reports (2021) Vol. 15, pp. 36-38
Open Access | Times Cited: 7
Baricitinib rapidly relieves eczema associated pruritus in elderly patients
Narang Hong, So Yun Park, Hyung Don Kook, et al.
Dermatologic Therapy (2022) Vol. 35, Iss. 9
Open Access | Times Cited: 4
Effects of abrocitinib on pruritus and eczema symptoms and tolerance in patients with moderate‑to‑severe atopic dermatitis in randomized, double‑blind and placebo‑controlled trials: A systematic review and a meta‑analysis
Xingxing Xie, Jie Zhang, Fujing Huang, et al.
Biomedical Reports (2024) Vol. 20, Iss. 5
Open Access
Baricitinib for Prurigo Nodularis: A Pilot Study on Efficacy and Safety
Padcha Pongcharoen, C Tuchinda, Panlop Chakkavittumrong, et al.
Dermatologic Therapy (2024) Vol. 2024, pp. 1-6
Open Access
Oral Janus Kinase Inhibitors in Pediatric Atopic Dermatitis
Elsy M. Navarrete-Rodríguez, Désirée Larenas‐Linnemann, Helena Vidaurri‐de la Cruz, et al.
Current Allergy and Asthma Reports (2024) Vol. 24, Iss. 9, pp. 485-496
Closed Access
Baricitinib for the Treatment of Chronic Pruritus of Unknown Origin
Wei Hua, Yingrou Tan, Hong Liang Tey
Dermatologic Therapy (2024) Vol. 2024, Iss. 1
Open Access
Baricitinib provides rapid and sustained improvements in absolute EASI and SCORAD outcomes in adults with moderate-to-severe atopic dermatitis
Jacob P. Thyssen, Thomas Bieber, C. Elise Kleyn, et al.
Journal of Dermatological Treatment (2023) Vol. 34, Iss. 1
Open Access | Times Cited: 1
A detailed evaluation of the effect of dupilumab on sleep in adults with atopic dermatitis
Erika Yue Lee, Aaron M. Drucker
British Journal of Dermatology (2023) Vol. 189, Iss. 6, pp. 649-655
Closed Access
Page 1

Scroll to top